Tbh was a little surprised not to see any mention of individual patient analysis for the phase 2 trial. I thought this was mentioned in the agm video as one of their follow up actions. One can only assume nothing positive came of it so they did not announce it.
Nothing much exciting in this announcement, though it is good to see that patient 1 is still doing well, and still improving after 3 years.
I see they’ve officially added pericytes to their pipeline. How long do you guys think it will take until they get something tangible out of it?
Ann: NTCELL and Parkinson's Clinical Trial Update, page-12
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.6¢ | $41.21K | 6.825M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 3056700 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 913000 | 5 |
View Market Depth
| Last trade - 15.36pm 27/09/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |